Biomarkers in drug discovery and development
- 30 April 2008
- journal article
- review article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 57 (2) , 85-91
- https://doi.org/10.1016/j.vascn.2007.10.002
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Idiosyncratic Toxicity: A Convergence of Risk FactorsAnnual Review of Medicine, 2007
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Pricing medicines: theory and practice, challenges and opportunitiesNature Reviews Drug Discovery, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Key factors in the rising cost of new drug discovery and developmentNature Reviews Drug Discovery, 2004
- Biomarkers, Validation and Pharmacokinetic-Pharmacodynamic ModellingClinical Pharmacokinetics, 2003
- The further evolution of biotechNature Reviews Drug Discovery, 2003
- C-reactive protein: history and revivalEuropean Journal of Internal Medicine, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001